Literature DB >> 10221288

Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.

R B Ostroff1, J C Nelson.   

Abstract

BACKGROUND: At low doses, risperidone acts as a 5-HT2 antagonist. Preclinical data suggest 5-HT2 antagonists may enhance the action of serotonin. This report examines the clinical use of risperidone to augment selective serotonin reuptake inhibitor (SSRI) anti-depressants in patients who have not responded to SSRI therapy.
METHOD: In 8 patients with major depressive disorder without psychotic features (DSM-IV) who had not responded to an SSRI, risperidone was added to the ongoing SSRI treatment. Hamilton Rating Scale for Depression scores were obtained before and after the addition of risperidone.
RESULTS: These 8 patients remitted within 1 week of the addition of risperidone. Risperidone also appeared to have beneficial effects on sleep disturbance and sexual dysfunction.
CONCLUSION: Risperidone may be a useful adjunct to SSRIs in the treatment of depression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221288     DOI: 10.4088/jcp.v60n0410

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  38 in total

Review 1.  Bipolar depression: management options.

Authors:  Gin S Malhi; Philip B Mitchell; Shahzad Salim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Using Atypical Antipsychotics in Primary Care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-12

Review 3.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

4.  Atypical antipsychotics for mood and anxiety disorders: safe and effective adjuncts?

Authors:  Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2005-07       Impact factor: 6.186

5.  An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression.

Authors:  Jeremy Barowsky; Thomas L Schwartz
Journal:  Psychiatry (Edgmont)       Date:  2006-07

Review 6.  Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04       Impact factor: 5.270

Review 7.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 8.  Use of atypical antipsychotics for treatment-resistant major depressive disorder.

Authors:  George I Papakostas; Richard C Shelton
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

Review 9.  Treating bipolar disorder. Evidence-based guidelines for family medicine.

Authors:  Roger S McIntyre; Deborah A Mancini; Peter Lin; John Jordan
Journal:  Can Fam Physician       Date:  2004-03       Impact factor: 3.275

10.  Augmentation treatment in major depressive disorder: focus on aripiprazole.

Authors:  J Craig Nelson; Andrei Pikalov; Robert M Berman
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.